AMX0035
Phase 2/3Active 0 watching 0 views this week๐ Rising
60
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Trial Timeline
Dec 21, 2023 โ Nov 30, 2029
NCT ID
NCT06122662About AMX0035
AMX0035 is a phase 2/3 stage product being developed by Amylyx Pharmaceuticals for Progressive Supranuclear Palsy. The current trial status is active. This product is registered under clinical trial identifier NCT06122662. Target conditions include Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05286372 | Pre-clinical | Completed |
| NCT06122662 | Phase 2/3 | Active |
| NCT05676034 | Phase 2 | Active |
| NCT05619783 | Phase 3 | Completed |
| NCT05021536 | Phase 3 | Active |
| NCT04987671 | Phase 1/2 | UNKNOWN |
| NCT04516096 | Phase 2/3 | Completed |
| NCT03488524 | Phase 2 | Completed |
| NCT03127514 | Phase 2 | Completed |
Competing Products
20 competing products in Progressive Supranuclear Palsy